6533b822fe1ef96bd127d8d3

RESEARCH PRODUCT

Trabectedin for patients with advanced soft tissue sarcoma: A non-interventional, retrospective, multicenter study of the italian sarcoma group

Giuseppe BadalamentiIrene QuattriniAlberto RighiF. ZanelliLibero CiuffredaAngela BuonadonnaElisabetta SetolaPiero PicciRoberta SanfilippoVittorio FerrariFabio GelsominoAntonella RomaniniToni IbrahimMaria Abbondanza PantaleoLaura MilesiGiovanni GrignaniEmanuela MarchesiFederica GrossoEmanuela PalmeriniElisa CarrettaAlessandro ComandoneVirginia FerraresiBruno VincenziStefano FerrariAntonio PizzolorussoAntonella BrunelloTommaso De Pas

subject

0301 basic medicineLeiomyosarcomaCancer Researchmedicine.medical_specialtyDacarbazinelcsh:RC254-282GastroenterologyArticlePazopanib03 medical and health sciences0302 clinical medicineInternal medicinemedicineProgression-free survivalObservationalTrabectedinSoft tissue sarcomaPerformance statusbusiness.industrySoft tissue sarcomaReal-lifelcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensmedicine.disease030104 developmental biologyOncology030220 oncology & carcinogenesisSarcomabusinessmedicine.drugTrabectedin

description

The Italian Sarcoma Group performed this retrospective analysis of patients with advanced soft tissue sarcoma, pretreated with ≥1 anthracycline-based treatment, and treated with trabectedin every three weeks. Primary endpoint was to describe real-life use of trabectedin across Italy. Secondary endpoints included objective response rate (ORR) and safety. Overall, 512 patients from 20 Italian centers were evaluated. Leiomyosarcoma (37.7%)/liposarcoma (30.3%) were the most prevalent histological types (abbreviated as L-sarcoma). Patients received a median of four trabectedin cycles (range: 1–40), mostly as a second-line treatment (~60% of patients). The ORR was 13.7% superior (p &lt

yearjournalcountryeditionlanguage
2021-03-02
10.3390/cancers13051053http://hdl.handle.net/11585/864350